Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.
"The biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation," as published in the journal Food and Chemical Toxicology.
